Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
These injections are the first of their kind and the first approved drug for chronic weight management since 2014
The market for these drugs is currently dominated by brand-name products, and their high prices reflect this lack of competition
Exogenous iron induces NADPH oxidases-dependent ferroptosis in the conidia of Aspergillus flavus
Tirzepatide Recent Developments In September 2025, Eli Lilly and Company announced detailed results from SURPASS-PEDS, the first Phase III trial to evaluate the safety and efficacy of MOUNJARO (tirzepatide), a GIP/GLP-1 dual receptor agonist, in children and adolescents (ages 10 to less than 18) with type 2 diabetes inadequately controlled with metformin, basal insulin or both
US$ 23.21
US$ 24.23
US$ 28.09
US$ 25.30
US$ 25.45
US$ 26.42
US$ 27.11
US$ 24.94
US$ 21.11
US$ 23.44
US$ 25.26
US$ 23.84
